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Sebaceous carcinomas are rare cutaneous appenda-
geal tumors that may occur sporadically or in asso-
ciation with an internal malignancy in Muir±Torre
syndrome. In Muir±Torre syndrome microsatellite
instability can often be demonstrated in tumor DNA
as a result of an inherited mutation in one of several
known mismatch repair genes; however, the role of
microsatellite instability in sporadic sebaceous carci-
nomas has not been previously studied. In this report
we describe the clinicopathologic characteristics of a
series of unselected sebaceous carcinomas and exam-
ine them for the presence of microsatellite instability.
Of 10 consecutive tumors identi®ed over a 10 y per-
iod, only one was from a patient known to have
Muir±Torre syndrome. Of the nine presumed spora-
dic cases, ®ve were from four renal transplant recipi-
ents and four from otherwise healthy individuals.
Microsatellite instability was demonstrable in three
cases: in the Muir±Torre syndrome-associated tumor
and in two tumors from transplant patients.
Microsatellite instability was subsequently also found
in a sebaceous carcinoma from a further transplant
patient prospectively sought from another institu-
tion. The presence of microsatellite instability in
post-transplant sebaceous carcinomas was associated
with loss of expression of the mismatch repair pro-
tein hMSH2. In summary, sebaceous gland carcino-
mas, while characteristic of Muir±Torre syndrome,
are commonly found outside this context. Among
presumed sporadic cases, our data suggest they may
be over-represented in immunosuppressed renal
transplant recipients. The presence of microsatellite
instability in transplant-associated lesions, together
with loss of hMSH2 expression suggests that immu-
nosuppression might unmask a previously silent
Muir±Torre syndrome phenotype in some cases.
Alternatively, there is experimental evidence to sug-
gest that immunosuppressive drugs, most plausibly
azathioprine, could select for the emergence of a
mutator phenotype and thus predispose to the devel-
opment of sebaceous carcinomas. The role of
mismatch repair defects in other post-transplant skin
malignancies remains to be established. Key words:
immunosuppression/mismatch repair defects/Muir±Torre
syndrome/skin cancer. J Invest Dermatol 116:246±253,
2001
S
ebaceous gland carcinomas (SGC) are rare cutaneous
appendageal tumors which may arise at ocular or
extraocular sites (Rulon and Helwig, 1974; Wick et al,
1985; Nelson et al, 1995). They have a well±recognized
association with Muir±Torre syndrome (MTS), an
autosomal dominant genodermatosis characterized by the con-
current or sequential development of sebaceous gland tumors
(adenoma, epithelioma, or carcinoma) and at least one internal
malignancy (Torre, 1968). A proportion of patients with MTS have
a strong family history of malignancy and show clinicopathologic
overlap with the hereditary nonpolyposis colorectal cancer
(HNPCC) syndromes, Lynch types I and II (Lynch et al, 1981).
In HNPCC there is a predisposition to the early onset of carcinoma
of the colon and endometrium in particular, but also an increased
prevalence of other malignancies, including the stomach, small
bowel, pancreas, urogenital tract, and larynx, together with a family
history of these neoplasms (Boland et al, 1998). These similarities
led Lynch to suggest that the MTS may be a fuller phenotypic
expression of the genetic abnormalities responsible for HNPCC
(Lynch et al, 1985).
Studies have demonstrated that almost all visceral tumors from
patients with HNPCC exhibit a type of genomic instability known
as microsatellite instability (MSI) at the majority of loci examined
(Aaltonen et al, 1993; Ionov et al, 1993; Thibodeau et al, 1993).
This instability manifests as changes in the size of tumor
microsatellite alleles compared with those from normal tissue. In
HNPCC, genomic instability is due to a defect in postreplicative
DNA mismatch repair (DNA MMR), a system which recognizes
and restores misincorporated bases or slippage errors which
frequently occur during DNA replication (Jiricny, 1998). An
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inherited mutation in one of at least 5 genes encoding MMR
proteins, namely hMSH2, hMLH1, hPMS1, hPMS2 and GTBP/
hMSH6 (Liu et al, 1996; Akiyama et al, 1997; Papadopoulos and
Lindblom, 1997) together with somatic inactivation of the
homologous wild-type allele results in a mutator phenotype
characterized by a high rate of base substitutions as well as
insertions and deletions in mononucleotide and dinucleotide
repeats (Parsons et al, 1993). MSI is also observed in sebaceous
and visceral tumors from patients with MTS (Honchel et al, 1994),
and further evidence that MTS is a phenotypic variant of HNPCC
is provided by the demonstration of germline mutations of hMSH2
and hMLH1 in some patients with MTS (Bapat et al, 1996; Esche
et al, 1997; Kruse et al, 1998). Tumorigenesis related to MSI is
believed to involve inactivating frameshift mutations of micro-
satellite repeats within coding regions of speci®c target genes,
including transforming growth factor-b type II receptor, insulin-
like growth factor-IIR, BAX, MSH3/MSH6, PTEN, and
adenomatous polyposis coli (reviewed in Boland et al, 1998).
The prevalence of MSI in sporadic carcinomas from the
HNPCC spectrum has been extensively studied and is present in
up to 15% of tumors in colon and endometrial cancers (Claij and te
Riele, 1999). Mutated MMR genes have been found in some
sporadic malignancies with MSI (Borresen et al, 1995; Liu et al,
1995), indicating that the mechanisms of tumorigenesis may be
similar, but there is also evidence for epigenetic inactivation of
MMR genes in some tumors (Kane et al, 1997; Herman et al, 1998;
Veigl et al, 1998; Gurin et al, 1999; Leung et al, 1999). Investigation
of sporadic tumors speci®cally associated with the MTS spectrum
has received less attention and in particular the prevalence of MSI
in sebaceous tumors, which are characteristic of MTS is not
known.
In this study we analyzed the clinical and histologic features of an
unselected series of SGC, and determined whether MSI is present
in such tumors outside the context of MTS.
MATERIALS AND METHODS
Patients and tissues Consecutive SGC were identi®ed from a review of
all sebaceous neoplasms from the histopathology database of over 100,000
samples archived in the Royal Hospitals NHS Trust between 1988 and
1998. Clinical details of past medical history, drug history and family history
were obtained from case notes. Material for microsatellite analysis was
available in nine cases. In addition, material was subsequently obtained
from King's College Hospital from a renal transplant recipient (RTR) (LB)
who had developed an extraocular SGC. Other nonsebaceous tumors from
these patients were also available for microsatellite analysis.
Histologic assessment Each of the tumors was histologically reviewed
by one pathologist (RC) without knowledge of the corresponding clinical
details. Strict criteria were used to con®rm the diagnosis of sebaceous
carcinoma and to distinguish the lesion from sebaceous adenoma and
sebaceous epithelioma (Finan and Connolly, 1984). A diagnosis of
sebaceous carcinoma was made if the tumor consisted of poorly de®ned
lobules and sheets with an in®ltrating border, lack of differentiation,
cytologic atypia, and variable sebaceous change. Sebaceous epitheliomas
and adenomas were not included in our study.
DNA extraction Tumor samples were microdissected to enrich for the
tumor cell population. Only tumor areas containing > 70% tumor cells
were used for DNA extraction. Blocks of formalin-®xed, paraf®n-
embedded archival tissue containing representative lesional and normal
tissue were selected. Twelve micrometer sections from formalin-®xed,
paraf®n-embedded archival tissue were de-waxed by two washes in xylene
for 30 min and dehydration in absolute alcohol. A 5 mm section taken
immediately before the 12 mm sections was stained with hematoxylin and
eosin and was used to aid the identi®cation of the relevant areas of tumor
and normal tissue. Under a dissecting microscope, a 21-gauge needle was
used to microdissect out these areas. The tissue was placed in 100 ml of 10%
Chelex-100 resin solution (iminodiacetic acid chelating resin, Sigma,
Poole, U.K.) containing 300 mg per ml proteinase K (Boehringer
Mannheim, Mannheim, Germany). The solution was incubated at 56°C
for 30 min while agitating gently every 5 min. The proteinase K was then
inactivated by boiling for 8 min. The samples were brie¯y vortexed,
centrifuged, and stored at 4°C. Normal, nontumor DNA was obtained by
microdissection of normal perilesional tissue from paraf®n blocks, or from
blood. Blood was collected in ethylenediamine tetraacetic acid-containing
collection tubes and genomic DNA was extracted from 1 to 10 ml using a
Nucleon BACC-3 extraction kit (Scotlab, Lanarkshire, U.K.) according to
the manufacturer's instructions. All molecular genetic analyses were
performed on the same DNA sample from each tumor.
Microsatellite analysis Analysis for replication errors was carried out by
polymerase chain reaction (PCR) ampli®cation of 11 highly polymorphic
dinucleotide microsatellite markers localized at 1p (D1S201), 1q (D1S214),
9q (D9S160 and D9S176), 9p (D9S162 and D9S171), 10q (D10S185), 13q
(D13S155), 17p (D17S520 and D17S796), and 17q (D17S785) obtained
from Research Genetics (Huntsville, AL). All primer pairs had reported
heterozygosity indices = 0.80 and were selected to include dinucleotides
involved in genetic alterations of melanoma and nonmelanoma skin cancer
(NMSC). Although not all tumors were investigated for all of these loci, a
minimum of six informative loci were examined for each patient. PCR was
performed in 10 ml reactions comprising 2 ml of DNA, 200 mM
deoxynucleotide triphosphates, 1 pmol of each primer (one end-labeled
with [g33P]adenosine triphosphate (Amersham, U.K.) and 1 unit of Taq
DNA polymerase (Biotaq, Bioline, London, U.K.). Ampli®cation was
carried out using a Robocycler Gradient 96 thermal cycler (Stratagene,
Cambridge, U.K.) and consisted of 30 cycles of 1 min at 95°C, 1 min at
55°C, and 1 min at 72°C with a ®nal 10 min extension time at 72°C.
Samples containing all PCR reagents with the exception of target DNA
were used as negative controls and subjected to the same ampli®cation
conditions as the tumor and nontumor samples and were consistently
negative. Ten microliters of loading buffer was added to each PCR
reaction; samples were heat denatured and electrophoresed through 6%
denaturing polyacrylamide gels. Gels were ®xed in 10% acetic acid/10%
methanol for 15 min, transferred to Whatmann paper and dried and imaged
using the STORM PhosphorImaging system (Molecular Dynamics,
Sunnyvale, CA). The relative intensities of the PCR products varied
between gels, and different phosphorimager software settings were used to
equalize intensities.
De®nition of MSI and loss of heterozygosity (LOH) Informative
normal tissues were de®ned as those with two ampli®ed bands on the gel
image, usually separated by 2±8 bp. MSI was de®ned as the presence of
unambiguously displayed additional bands in the PCR ampli®ed product
derived from tumor DNA (either expansion or contraction in repeat
length) compared with that derived from the control normal DNA from
that patient. Although there are no internationally agreed criteria for extra-
colonic tissue, criteria developed for the classi®cation of MSI in the colon
designate the degree of instability as high (MSI-H) if multiple novel alleles
are present at 40% loci examined (Boland et al, 1998). The presence or
absence of these novel microsatellite alleles was determined independently
by at least three reviewers; all samples were coded and interpreted without
knowledge of corresponding clinical details. LOH was scored if the signal
of one allele was clearly reduced in the tumor DNA as compared with the
corresponding normal alleles.
Immunostaining for hMSH2 and hMLH1 To determine the MMR
protein status, all tumors were immunohistochemically analyzed using
primary antibodies to hMSH2 and hMLH1. Four micrometer thick
sections of formalin-®xed, paraf®n-embedded tumor tissue were mounted
on 3-aminopropyltriethoxysilane/acetone-coated slides and deparaf®nized
in xylene for 10 min followed by rehydration in graded alcohol.
Endogenous peroxidase activity was blocked by treating sections in 3%
hydrogen peroxide in methanol for 10 min followed by washing in running
tap water for 2 min. Antigen retrieval was achieved by microwave
treatment (8 min at 900 W in preheated 10 mM citrate buffer pH 6.0),
and sections were washed again in running tap water. The sections were
washed in Tris-buffered saline buffer pH 7.6 for 5 min, the excess wiped off
with a Kimwipe, and nonspeci®c antibody binding was blocked by
incubation in 5% horse serum for 2 min. Excess horse serum was poured
off, and the primary antibody added to the section and incubated overnight
at 4°C in a humid chamber. For hMLH1 detection, a mouse monoclonal
antibody was used (clone G168±15; PharMingen, Becton Dickinson,
U.K.), and for hMSH2 a mouse monoclonal was used (clone G219±1129;
PharMingen), with both antibodies being used in a dilution of 1 : 150. After
washing in Tris-buffered saline, a secondary biotinylated antibody from a
universal ABC kit (Vectastain Universal Elite ABC Kit, Vector
Laboratories, Peterborough, U.K.) was applied for 40 min at room
temperature and rinsed again in Tris-buffered saline. The tertiary
peroxidase labeled avidin was applied for 30 min at room temperature.
Sections were developed for 5±10 min in 3,3¢-diaminobenzidine (Liquid
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Table I. Clinical details of patients with sebaceous carcinoma
Patient Sex Site of Immune Immuno- Duration of Other skin Visceral Family MSI analysisa
sebaceous status suppressive transplant to tumours tumours history of
carcinoma therapy sebaceous (number) (age at cancer (age Tumor No. of loci
(age at carcinoma diagnosis) at cancer displaying MSI (%)
diagnosis) diagnosis) and loss of hMSH2b
JG M Cheek (58) RTR A, P, C 3 BCC (8), Gastric Father: Ca 1. Sebaceous ca 6/7 (86)b
?MTS SCC (10) carcinoid lung (72 y) 2. Gastric carcinoid 0/6 (0)
(52 y) 3. SCC skin 0/6 (0)
4. SCC skin 0/6 (0)
5. BCC skin 0/6 (0)
HA M Lip (75) RTR A,P,C 8 BCC (1) Benign Mother: Ca 1. Sebaceous ca (®rst) 0/7 (0)
SCC (11) colonic colon (55 y)
polyp 2. Sebaceous ca (second) 0/6 (0)
(65 y)
3. SCC skin 0/6 (0)
BM M Ear (50) RTR A, P 28 KA (2) No No 1. Sebaceous ca 0/7 (0)
SCC (20) 2. SCC skin 0/6 (0)
DD M Back (59) RTR A, P, C 6 No No No Sebaceous ca 9/9 (100)b
CV M Cheek (73) ICP ± ± MM No No Sebaceous ca 0/7 (0)
EC M Cheek (73) ICP ± ± SCC (1) No No Sebaceous ca ND
SR F Temple (81) ICP ± ± No No No Sebaceous ca 0/7 (0)
CM F Leg (68) ICP ± ± No No No Sebaceous ca 0/7 (0)
EG M Back (41) MTS ± ± SA
(multiple),
SCC (2)
1. Cacecum (27 y)
2. Rectal adenoma
(35 y)
Father: Ca
colon and
larynx (45 y)
1. Sebaceous ca
2. Sebaceous
adenoma
3/6 (50)
0/7 (0)
3. Small bowel 3. SCC skin 1/6 (17)
adenocarcinoma 4. Small bowel 4/7 (57)
(41 y) adenocarcinoma
4. Duodenal
adenoma
(43 y)
LB M Back (70) RTR A, P, C 8 BCC (1) No Unknown Sebaceous ca 9/9 (100)b
SCC (1)
aLoci examined were localized to 1p (D1S201), 1q (D1S214), 9q (D9S160 and D9S176), 9p (D9S162 and D9S171), 10q (D10S185), 13q (D13S155), 17p (D17S520 and D17S796), and 17q (D17S785).
bLesions in which hMSH2 protein expression was absent. In all other lesions hMSH2 was present, and in all lesions hMLH1 was expressed.
ICP, immunocompetent; KA, keratoacanthoma; MM, malignant melanoma; SA, sebaceous adenoma; ND, not done (insuf®cient DNA obtained from biopsy material); A, azathioprine; P, prednisolone; C, cyclosporine; ca,
carcinoma.
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DAB substrate Pack, BioGenex, San Ramon, CA) as chromogen and then
washed in running tap water for 10 min. The sections were counterstained
with Gill's hematoxylin, dehydrated in graded alcohol, cleared in xylene for
4 min, and mounted in DePeX mounting medium (BDH, Poole, U.K.).
RESULTS
Ten lesions identi®ed in nine individuals were con®rmed as SGC
after detailed histologic review (Table I and Fig 1). One of these
patients (EG), aged 41 y, ful®lled the criteria for MTS; he had a past
history of multiple primary colorectal adenocarcinomas, multiple
sebaceous adenomas, and a cutaneous squamous cell carcinoma
(SCC); his father had both colorectal and laryngeal carcinomas and
his brother had died from a brain tumor as had his sister and a niece.
The remaining eight patients were not known to have MTS prior
to the diagnosis of sebaceous carcinoma. Of these eight presumed
sporadic cases, four were RTR, one of whom developed two SGC.
The remaining four were from otherwise immunocompetent
individuals
Clinical characteristics of renal transplant patients
(Table I) Tumor material from a ®fth RTR from another
transplant population was subsequently included in study for MSI
analysis; the clinical characteristics of this patient are included here
for completeness. All ®ve RTR received immunosuppression with
azathioprine, prednisolone, and cyclosporine (DD, JA, HA, LB) or
azathioprine and prednisolone only (BM). SGC was diagnosed at a
mean age of 60.4 y (range 50±75 y). In four RTR the SGC arose
less than 10 y after transplantation, the ®fth presenting 28 y after
transplantation. One patient (JG), ful®lled the current broad criteria
for MTS as he had previously had an internal malignancy, although
gastric carcinoid is not characteristic of the HNPCC spectrum and
has not been speci®cally reported in MTS. Four of the ®ve
transplant patients had a previous history of NMSC.
Clinical characteristics of immunocompetent patients
(Table I) Of the four immunocompetent patients, none had a
family or personal history of internal cancer. The mean age at
presentation of SGC was 73.8 y (range 68±81 y). Two of these four
patients also had a past history of skin cancer (CV and EC).
Microsatellite analysis (Tables I and II; Fig 2) One of the
sebaceous carcinomas could not be analyzed because of insuf®cient
tumor cell content in the paraf®n-embedded material. Of the
remaining 10 lesions (nine from our center and one other), four
showed evidence of MSI-H (Fig 2, Table II). Three of these were
from RTR (JG, DD, LB), and one was from the patient with a
known MTS (EG). Thus, three of ®ve (60%) sebaceous carcinomas
from RTR showed MSI compared with none of three (0%) from
immunocompetent individuals (p = 0.2, Fisher's exact test). Ten
nonsebaceous tumors from these patients were also examined for
MSI-H (Tables I and II), from those both with and without MSI
Figure 1. Sebaceous carcinoma from patient DD. Hematoxylin and
eosin stain, scale bar: 25 mm. The tumor is comprised of proliferating,
invasive islands of cells showing pleomorphism, mitoses, and sebaceous
differentiation, manifest as ®nely vacuolated or foamy cytoplasm, with
more differentiation at the center of the nests.
Figure 2. MSI in paired normal and tumor DNA. Microsatellite
analyses of DNA from paired control (C) and microdissected sebaceous
carcinoma tumor (T) at locus D1S201. Examples from three individuals are
shown: (a) patient BM; (b) patient JG; (c) patient DD. Tumors
demonstrating MSI are denoted T*; ® indicates two alleles of control
DNA; ¬ denotes additional bands due to MSI.
Figure 3. Immunohistochemical analysis of hMLH1 and hMSH2
expression in SGC. (a) hMLH1; (b) hMSH2. Strong nuclear staining with
hMLH1 is seen in the overlying normal epidermis of this sebaceous
carcinoma from RTR, JG (indicated by ¬). Nuclear staining is also seen
throughout the tumor (T). Strong nuclear staining in the overlying
epidermis (¬) is also seen with hMLH2; however, there is almost complete
loss of nuclear hMSH2 staining in the tumor (T). Scale bar: 50 mm.
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in their SGC. MSI-H was identi®ed in a small bowel
adenocarcinoma from the MTS patient (EG), and also detected at
one of six loci in a cutaneous SCC from this patient, but was not
present in a sebaceous adenoma. MSI was not found in any other
specimen, including four tumors from patient JG, despite detection
of MSI-H in his sebaceous carcinoma. All samples in which MSI
was detected were noted to demonstrate novel alleles of increased
length.
Immunohistochemical detection of hMLH1 and hMSH2
(Fig 3; Table I) All lesions showed intense nuclear staining for
hMLH1 in both tumor cells and normal epidermis, including
sebaceous glands. Nuclear staining of hMSH2 was absent in
sebaceous carcinomas from patients JG, DD, and LB (tumors from
RTR that had displayed MSI), although retained in surrounding
normal epidermis and sebaceous glands (Fig 3). Other tumors from
these individuals, which had not displayed MSI, correspondingly
showed normal staining for hMSH2. Tumors from other RTR
patients, which had not shown MSI, were positive for both
hMLH1 and hMSH2, as were those from immunocompetent
patients with SGC. All lesions from the patient with MTS (EG),
both microsatellite stable and unstable were also were positive for
both hMLH1 and hMSH2.
DISCUSSION
In this study we examine an unselected series of 10 sebaceous
carcinomas from nine individuals, only one of whom subsequently
turned out to have an unequivocal diagnosis of MTS. Unexpect-
edly, four of eight patients with presumed sporadic sebaceous
carcinoma were RTR; one of these also broadly ful®lled the
criteria for MTS (in retrospect), although this diagnosis had not
previously been made. Molecular analysis of nine of these tumors,
together with tumor from a ®fth transplant patient, con®rmed the
presence of MSI in four of 10 lesions; two from patients who
ful®lled criteria for MTS (including one RTR), and two from
RTR who did not. MSI-H was not present in any of the three
sporadic sebaceous carcinomas from otherwise healthy individuals.
MSI in tumors from RTR was associated with loss of hMSH2
expression as determined by immunohistochemistry. Finally, six of
the 10 patients with sebaceous carcinoma also had at least one other
cutaneous malignancy.
Clinicopathologic context of unselected sebaceous
tumors Sebaceous carcinomas are rare, and probably best
known in the context of MTS where most of the studies have
been focused to date. In this study only one of nine patients had
MTS, although arguably, a further patient (JG) also ful®lled the
broad criteria for this syndrome. Thus seven of nine cases were
most likely sporadic. Four of our cases, and three of the seven
presumed sporadic cases (43%) were RTR, which was an
unexpected ®nding as it is not a currently recognized association.
Sebaceous hyperplasia is common after organ transplantation (De
Berker et al, 1996), but this is the ®rst time an increased prevalence
of SGC has been reported. The rarity of the tumor, and the
occurrence of ®ve lesions in four transplant patients in a single series
certainly suggests that the association is real, even allowing for
ascertainment bias. Ours was not intended to be a population-based
study, but it is possible to calculate an approximate incidence of
sebaceous carcinomas for transplant compared with nontransplant
populations; four from our cohort of 650 transplant patients
developed SGC (0.62%, 95% con®dence interval 0.21±1.8%),
compared with four nontransplant patients from a population base
of 605,000 (6.6 3 10±4%, 95% con®dence interval 2.12 3 10±4±
1.82 3 10±3), p < 10±6.
There is one previous study of unselected sebaceous tumors (i.e.,
Finan and Connolly, 1984) that reviewed all sebaceous adenomas,
epitheliomas, and carcinomas removed between 1923 and 1983 at
the Mayo Clinic. They observed that 25 patients of a total of 59
(42.3%) had an associated visceral cancer, 18 (30.5%) of whom also
had a family history of cancer and ful®lled criteria for MTS. They
do not comment on the immune status of their patients; however,
their data, like ours, suggest that the majority of patients with SGC
do not have MTS.
There are several possible reasons why an increased prevalence of
SGC has not previously been noted among transplant recipients,
perhaps foremost because such lesions are being classi®ed as SCC
with sebaceous differentiation, rather than SGC. We used strict
Table II. Details of MSI status of all lesions examined at individual microsatellite markers
Pt Immune Lesion Microsatellite instability at individual loci
status
D1S201 D1S214 D9S160 D9S162 D9S176 D9S171 D1OS185 D13S155 D17S520 D17S796 D17S785
JG RTR 1. Sebaceous ca a + + a a + ± + a + +
2. Gastric LOH ± ± a a ± ± ± a ± ±
carcinoid
3. SCC skin ± ± ± a a ± ± ± a ± ±
4. SCC skin ± ± ± a a ± LOH ± a ± ±
5. BCC skin ± ± ± a a ± ± ± a ± ±
HA RTR 1. Sebaceous ca ± ± ± ± a ± ± ± ± ± ±
2. Sebaceous ca ± ± ± a a ± ± ± a LOH ±
3. SCC skin ± ± ± a a ± ± ± a ± ±
BM RTR 1. Sebaceous ca ± ± ± ± a ± ± ± ± ± LOH
2. SCC skin ± ± ± a a ± LOH ± a ± ±
DD RTR Sebaceous ca + + + + a + + + + + +
CV ICP Sebaceous ca ± ± ± ± a ± ± ± ± ± ±
SR ICP Sebaceous ca ± FA ± ± a ± FA ± ± ± ±
CM ICP Sebaceous ca LOH FA ± ± a ± FA ± ± ± ±
EG MTS 1. Sebaceous ca + FA ± a + FA a + ± FA ±
2. Sebaceous ± a ± a ± FA a FA FA ± ±
adenoma
3. SCC skin + a ± a ± ± a FA ± FA ±
4. Small bowel ± a + a + FA FA + + FA +
adenocarcinoma
LB RTR Sebaceous ca + + + + a + FA + + + +
+, MSI present; ±, MSI not detected; aMSI not tested at this locus; FA, marker failed to amplify; LOH, loss of heterozygosity but no MSI; ca, carcinoma.
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criteria to diagnose sebaceous tumors for this series, and it is our
experience that sebaceous differentiation is rare in SCC, even in
transplant patients. In two studies comparing 342 consecutive,
unselected, primary cutaneous SCC (n = 117) and basal cell
carcinomas (BCC; n = 225) from RTR and immunocompetent
individuals, < 0.5% of SCC from both groups showed sebaceous
differentiation, and when present this never constituted more than
10% of the total tumor (Harwood et al, 1996, 1998).
In fact, although an association has not been formally highlighted
before, there are anecdotal reports of sebaceous tumors arising in
RTR and other immunosuppressed patients in the literature. Stone
et al (1986) reported a patient with known MTS in whom multiple
sebaceous adenomas developed after immunosuppression with
cyclosporine and prednisolone following cardiac transplantation.
Another patient developed an ocular sebaceous carcinoma follow-
ing cardiac transplantation, and subsequently ful®lled criteria for
MTS when he developed an adenocarcinoma of the colon. He also
had a strong family history of colonic and uterine malignancies
(Stockl et al, 1995), as did a third cardiac transplant patient who also
developed multiple sebaceous neoplasms and colon cancer after the
introduction of immunosuppression (Paraf et al, 1995). Cohen
(1992) described a man with Hodgkin's lymphoma and a sebaceous
carcinoma of the upper eyelid and in another case report, a single
rapidly growing sebaceous adenoma presented in a patient with
acquired immune de®ciency syndrome and Kaposi's sarcoma, but
there was no history of visceral malignancy (Dover et al, 1988).
Another patient with previous transitional cell carcinoma of the
urinary tract and a family history of colonic adenocarcinoma
presented with multiple sebaceous adenomas and a keratoacantho-
ma after developing acquired immune de®ciency syndrome.
Finally, Warschaw et al (1997) described a patient with adeno-
carcinoma of the colon and sebaceous adenoma, presumed to be
MTS, who subsequently developed multiple further sebaceous
tumors and a poorly differentiated adenocarcinoma of the skin
coincident with human immunode®ciency virus infection and a fall
in CD4 count; microsatellite analysis of tumor DNA in this case
revealed widespread MSI.
This needs con®rmation in other transplant populations but our
data, together with case reports already in the literature, indicate
that immunosuppression may indeed predispose to the develop-
ment of sebaceous tumors.
MSI in sebaceous carcinomas The presence of MSI is well
established in sebaceous tumors from patients with MTS (Honchel
et al, 1994; Esche et al, 1997; Peris et al, 1997b; Kruse et al, 1998),
but its role in the development of sporadic tumors has not been
addressed before. In a previous study of tumors from 13 presumed
MTS patients (Honchel et al, 1994) (including 13 sebaceous
tumors, four of which were sebaceous carcinomas), MSI-H was
found in three of four sebaceous carcinomas and in a variety of
epitheliomas and adenomas in six patients, but was not detectable in
any tumor in seven patients. That MSI was only demonstrable in
approximately 50% of cases in this series could re¯ect either the
limitations of MSI detection and/or the currently wide de®nition
of MTS, embracing as it does any internal malignancy in
combination with a sebaceous tumor. In another study using a
more rigorous de®nition of MTS, i.e., the occurrence of both a
sebaceous tumor and colorectal cancer, MSI-H was found in at least
one tumor from all 16 patients, including 18 of 22 sebaceous
tumors (Kruse et al, 1998).
The patient in our series with MTS ful®lled the strict criteria
applied in Kruse's study, and similarly showed MSI-H in sebaceous
and bowel tumor material. In the majority of MTS tumors
examined this appears to be the result of a germline mutation in the
gene encoding hMSH2 together with somatic mutation arising in
the tumor material, with subsequent loss of protein expression in
the tumor on immunocytochemistry. In some MTS cases,
however, mutations are not detected in either hMSH2 or hMLH1
(Kruse et al, 1996, 1998; RuÈtten et al, 1999), and the defect is
presumed to arise from a mutation in other MMR genes. This
plausibly explains our ®nding of retained hMSH2 expression in the
tumor material of one of the MTS patients (EG) despite
demonstration of MSI.
To what extent MSI contributes to sporadic sebaceous
carcinomas remains to be established. We found MSI in three of
nine sebaceous carcinomas that were presumed to be sporadic
(30%), or two of eight lesions (25%) if patient JG is classi®ed as
having MTS; however, the lesions in which we found MSI were all
from transplant recipients, none of three sporadic tumors from
immunocompetent patients exhibiting MSI. Thus we can conclude
that MSI contributes to the development of some sebaceous
carcinomas outside the context of MTS, but in our series only in
the context of organ transplantation. The numbers are too small to
employ statistical analysis and we cannot exclude that MSI might
also contribute to the development of some sporadic sebaceous
carcinomas in immunocompetent patients as well. The literature
reveals only two further case reports of MSI in what were presumed
to be sporadic sebaceous tumors. One of these, a sebaceous tumor
excised from an otherwise healthy 54 y old man, showed
widespread tumor MSI. This was subsequently shown to result
from a germline mutation in the hMLH1 gene, which suggests that
this patient actually had MTS and was at risk of developing an
internal malignancy with time (Kruse et al, 1999). The other
describes MSI at two of three loci in one of three sebaceous
epitheliomas from a patient with multiple sebaceous tumors but no
evidence of internal malignancy or immunosuppression (Ueda et al,
1999).
It is notable that the instability demonstrated in all lesions in our
series consisted of novel alleles of increased size, whereas the trend
in colorectal carcinomas from HNPCC individuals appears to be
for shortened rather than elongated alleles (Dietmaier et al, 1997).
In publications in which MSI in skin lesions from MTS and other
immunosuppressed patients is illustrated, however, the majority
also show increased allele lengths in a pattern very similar to that
observed in our study (Honchel et al, 1994; Quinn et al, 1995;
Warschaw et al, 1997; Kruse et al, 1998). This apparent difference
has not previously been highlighted, but may provide insight into
the nature and etiology of the MSI observed in MTS and
transplant-associated sebaceous carcinomas.
The role of MSI in sebaceous and nonsebaceous skin
cancers The characteristic spectrum of malignancy seen in
MTS and HNPCC suggests that MSI plays a predominant part in
the development of a speci®c range of tumor types. Thus MSI-H is
frequently seen in tumors of sebaceous gland, uterine cervix,
bowel, and gastric origin in MTS and HNPCC patients. Up to 15%
of equivalent sporadic visceral tumors also demonstrate MSI,
although often not MSI-H, and our data indicate that some
sporadic sebaceous tumors also demonstrate MSI-H, at least in the
context of post-transplantation.
For nonsebaceous skin tumors, that lie outside the characteristic
MTS/HNPCC spectrum it is not clear to what extent MSI might
be involved. The available evidence suggests that MSI is extremely
uncommon in sporadic NMSC; Quinn et al (1995) analyzed 135
sporadic NMSC from immunocompetent individuals (47 BCC, 49
SCC, 19 actinic keratoses and 20 carcinomas in situ). Only one
lesion (0.74%) demonstrated MSI-H by the criteria used in our
study. In a smaller study (Peris et al, 1997a), MSI was detected in
two of 21 keratoacanthomas (9.5%) from immunocompetent
patients, but no samples quali®ed as MSI-H. JimeÁnez et al (1998)
found no evidence of MSI in 30 immunocompetent cutaneous
SCC. Nonetheless, an abnormal cutaneous phenotype has been
described in HNPCC patients on sun-exposed but not sun-
protected skin, suggesting a role for MMR in at least some aspects
of ultraviolet-induced DNA damage (Swale et al, 1999). In
addition, several MTS patients have been reported with NMSC,
including keratoacanthomas, BCC, actinic keratoses, and malignant
melanomas, suggesting they may be at increased risk. To what
extent this re¯ects ascertainment bias is not clear but MSI-H has
been demonstrated in a number of these lesions, suggesting that the
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defect in DNA replication in MTS may contribute to the
development of skin cancers in these patients (Honchel et al,
1994; Kruse et al, 1998); however, even in patients with known
MTS where a germline defect of MMR is con®rmed, MSI may
only be demonstrable in up to 50% of NMSC (Honchel et al, 1994;
Kruse et al, 1998).
In our series of 10 patients with sebaceous carcinoma, seven also
had NMSC, including one immunocompetent patient with an
SCC, the MTS patient with two SCC and four transplant patients
with a total of 42 SCC, 10 BCC, and two keratoacanthomas.
Common causal factors might include ultraviolet exposure (both
NMSC and sebaceous carcinoma have a predilection for the head
and neck), human papillomavirus [which has been detected in a
proportion of ocular sebaceous carcinomas (Hayashi et al, 1994) and
NMSC (Harwood et al, 2000)], or conceivably, a MMR defect.
We were able to analyze six further skin tumor samples for MSI
from our patients, including four that demonstrated MSI in their
sebaceous carcinoma. MSI-H was found in one of six loci in an
SCC from the MTS patient (EG), but was absent in ®ve other skin
cancers, including three from renal transplant patient JG who
clearly showed MSI-H in his sebaceous carcinoma (Table I). Other
data also suggest that MSI is rare in transplant-associated skin
cancers: circumstantial evidence is provided by the report of
Rehman et al (1997) who compared LOH in SCC/carcinoma in
situ/actinic keratoses from RTR (n = 32) and immunocompetent
(n = 96) individuals. MSI was not recorded in any of the tumors
examined, including those from the transplant patients. The
absence of demonstrable MSI, however, does not necessarily
preclude a contribution of the MMR defect to the development of
NMSC as there is some recent evidence that MMR proteins may
indirectly affect the ef®ciency of the nucleotide excision repair
pathway (Bailis and Rothstein, 1990; Mellon and Champe, 1996;
Bertrand et al, 1998; Sancar, 1999). This could explain, at least in
part, the seemingly high prevalence of NMSC in MTS patients and
also in our series of patients with sebaceous carcinoma, even in the
absence of MSI.
The role of immunosuppression in the development of
sebaceous carcinoma Why renal transplant and possibly other
immunosuppressed patients should be at risk of SGC remains to be
established. In some previous case reports, and in at least one of the
transplant patients (JG) in our series, it seems that
immunosuppression may have unmasked the expression of a
latent MTS phenotype. This is unlikely, however, to account for all
cases as two transplant patients in our series had MSI negative
sebaceous tumors and two others with MSI-positive tumors were
otherwise entirely well. An alternative explanation is the
interaction of immunosuppressive drugs, and perhaps azathioprine
in particular, with DNA MMR mechanisms and with the
consequent emergence of an iatrogenically induced mutator
phenotype. It has been proposed from experimental models that
chronic exposure to azathioprine could select for cells with a MMR
de®cit as a mechanism for evading its cytotoxic effects (Swann et al,
1996). Glaab et al (1998) showed that in vitro resistance to 6-
thioguanine, a metabolite of azathioprine, is indeed associated with
an increased mutation rate in MMR-defective cells and suggested
that this might predispose in vivo to tumors in patients treated with
azathioprine. Our data would be consistent with this,
demonstrating a high prevalence of sebaceous carcinomas, a
proportion of which showed MSI, in transplant patients exposed
to long-term azathioprine.
In summary, we report a novel association between sebaceous
carcinoma and iatrogenic immunosuppression. The presence of
MSI in a proportion of tumors from RTR suggests either that
immunosuppression unmasks a latent MTS phenotype, or that
there might be an interaction between DNA MMR proteins and
immunosuppressive drugs, most plausibly azathioprine. Whether
defective MMR is relevant to other post-transplant skin malig-
nancies, either directly or indirectly via an interaction with
nucleotide excision repair, remains to be established.
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